These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31145885)

  • 21. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system.
    Weisberg E; Bateson D; McGeechan K; Mohapatra L
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):5-14. PubMed ID: 24229367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: a randomized controlled trial.
    Brito MB; Ferriani RA; Meijers JC; Garcia AA; Quintana SM; Silva de Sá MF; Vieira CS
    Thromb Res; 2012 Sep; 130(3):355-60. PubMed ID: 22542366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-year follow-up of immediate postpartum contraceptive implant insertion in adolescents.
    Barbieri MM; Dantas-Silva A; Caleffi LS; Morais SS; Juliato CRT; Bahamondes L; Surita FG
    Eur J Contracept Reprod Health Care; 2023 Feb; 28(1):58-64. PubMed ID: 36287505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuation of the etonogestrel implant in women undergoing immediate postabortion placement.
    Madden T; Eisenberg DL; Zhao Q; Buckel C; Secura GM; Peipert JF
    Obstet Gynecol; 2012 Nov; 120(5):1053-9. PubMed ID: 23090522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptability of ENG-releasing subdermal implants among postpartum Brazilian young women during the COVID-19 pandemic.
    Barbieri MM; Herculano TB; Dantas Silva A; Bahamondes L; Juliato CRT; Surita FG
    Int J Gynaecol Obstet; 2021 Jul; 154(1):106-112. PubMed ID: 33656758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Six- and twelve-month documented removal rates among women electing postpartum inpatient compared to delayed or interval contraceptive implant insertions after Medicaid payment reform.
    Crockett AH; Pickell LB; Heberlein EC; Billings DL; Mills B
    Contraception; 2017 Jan; 95(1):71-76. PubMed ID: 27400823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial.
    Gurtcheff SE; Turok DK; Stoddard G; Murphy PA; Gibson M; Jones KP
    Obstet Gynecol; 2011 May; 117(5):1114-1121. PubMed ID: 21508750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing of Etonogestrel Implant Insertion After Dilation and Evacuation: A Randomized Controlled Trial.
    Cowett AA; Ali R; Cooper MA; Evans M; Conzuelo G; Cremer M
    Obstet Gynecol; 2018 May; 131(5):856-862. PubMed ID: 29630023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study.
    Griffin L; Hammond C; Liu D; Rademaker AW; Kiley J
    Contraception; 2017 Jun; 95(6):564-570. PubMed ID: 28238839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-year observational study of immediate post-abortion insertion versus menstrual insertion of etonogestrel contraceptive implant.
    Zheng W; Tang Y; Wang C; Niu X; Qian Z; Huang L
    BMC Womens Health; 2021 Dec; 21(1):436. PubMed ID: 34965871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
    Ragazini CS; Bahamondes MV; Prandini TR; Brito MB; Amaral E; Bahamondes L; Duarte G; Quintana SM; Ferriani RA; Vieira CS
    Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):285-9. PubMed ID: 27227739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
    Clure C; Sheeder J; Lazorwitz A
    Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: A Randomized Controlled Trial.
    Edelman AB; Kaneshiro B; Simmons KB; Hauschildt JL; Bond K; Boniface ER; Jensen JT
    Obstet Gynecol; 2020 Aug; 136(2):323-332. PubMed ID: 32649493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data.
    Meirik O; Brache V; Orawan K; Habib NA; Schmidt J; Ortayli N; Culwell K; Jackson E; Ali M;
    Contraception; 2013 Jan; 87(1):113-20. PubMed ID: 23063337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twelve-month Continuation of the Etonogestrel Implant in Adolescents With Polycystic Ovary Syndrome.
    Buyers E; Sass AE; Severn CD; Pyle L; Cree-Green M
    J Pediatr Adolesc Gynecol; 2021 Feb; 34(1):33-39. PubMed ID: 32919086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuation rates of the subdermal contraceptive Implanon(®) and associated influencing factors.
    Teunissen AM; Grimm B; Roumen FJ
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):15-21. PubMed ID: 24329119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bleeding profile in users of an etonogestrel sub-dermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in Italian population.
    Di Carlo C; Guida M; De Rosa N; Sansone A; Gargano V; Cagnacci A; Nappi C
    Gynecol Endocrinol; 2015 Jun; 31(6):491-4. PubMed ID: 26213863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year continuation of the etonogestrel contraceptive implant in women with postabortion or interval placement.
    Mark A; Sonalkar S; Borgatta L
    Contraception; 2013 Nov; 88(5):619-23. PubMed ID: 23790436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study.
    Schnabel P; Merki-Feld GS; Malvy A; Duijkers I; Mommers E; van den Heuvel MW
    Clin Drug Investig; 2012 Jun; 32(6):413-22. PubMed ID: 22540269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinical evaluation of bleeding patterns, adverse effects, and satisfaction with the subdermal etonogestrel implant among postpartum and non-postpartum users.
    Wahab NA; Rahman NA; Mustafa KB; Awang M; Sidek AA; Ros RM
    Int J Gynaecol Obstet; 2016 Feb; 132(2):237-8. PubMed ID: 26617248
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.